Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kestra Medical TechnologiesKMTS -2.34%10 EV-to-EBITDA is -9.11 as of Jul. 15, 2026. GuruFocus rates KMTS with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 511 Medical Devices & Instruments companies, Kestra Medical Technologies ranks worse than 195694.52% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kestra Medical Technologies's enterprise value is $1,166.70 Mil.
Kestra Medical Technologies's EBITDA for the trailing twelve months (TTM) ended in Jan. 2026 was $-128.00 Mil. Therefore, Kestra Medical Technologies's EV-to-EBITDA for today is -9.11.
The historical rank and industry rank for Kestra Medical Technologies's EV-to-EBITDA or its related term are showing as below:
KMTS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.44 Med: -9.4 Max: -5.67
Current: -9.11
During the past 4 years, the highest EV-to-EBITDA of Kestra Medical Technologies was -5.67. The lowest was -18.44. And the median was -9.40.
KMTS's EV-to-EBITDA is ranked worse than 100% of 511
companies
in the Medical Devices & Instruments industry
Industry Median: 14.2
vs KMTS: -9.11
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Kestra Medical Technologies (NAS:KMTS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kestra Medical Technologies's PE Ratio (TTM) for today is calculated as:
Kestra Medical Technologies's share price for today is $24.24.
Kestra Medical Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.960.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kestra Medical Technologies EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kestra Medical Technologies's EV-to-EBITDA falls into.
Kestra Medical Technologies's current Enterprise Value is $1,166.70 Mil.
Kestra Medical Technologies's EBITDA for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-128.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kestra Medical Technologies (KMTS) has a EV-to-EBITDA of -9.11 as of Jul. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kestra Medical Technologies. According to the industry distribution chart, Kestra Medical Technologies ranks #999999 out of 511 companies in the Medical Devices & Instruments industry.
Is Kestra Medical Technologies' EV-to-EBITDA too high?
Kestra Medical Technologies' current EV-to-EBITDA is -9.11. Based on the distribution chart, Kestra Medical Technologies ranks #999999 out of 511 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Kestra Medical Technologies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' EV-to-EBITDA compare to ATRC and STAA?
According to the Medical Devices & Instruments industry distribution chart, Kestra Medical Technologies ranks #999999 out of 511 companies for EV-to-EBITDA. This places Kestra Medical Technologies in the lower half of its industry. The industry median EV-to-EBITDA is 14.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.20, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kestra Medical Technologies. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kestra Medical Technologies's current EV-to-EBITDA is -9.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current EV-to-EBITDA of -9.11. The current EV-to-EBITDA is -9.11. Kestra Medical Technologies' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current EV-to-EBITDA is -9.11 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
10GF Score
Get the complete analysis for KMTS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMTS has been successfully added to your 
